Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib

Sunitinib has been approved for the treatment of advanced and/or metastatic renal cell carcinoma (RCC). Information on the dosage adjustment of sunitinib for patients undergoing hemodialysis is limited. Especially, efficacy and tolerance of sunitinib at a low dose in such patients are not fully unde...

Full description

Bibliographic Details
Main Authors: Satoshi Noda, Susumu Kageyama, Teruhiko Tsuru, Shigehisa Kubota, Tetsuya Yoshida, Keisei Okamoto, Yusaku Okada, Shin-ya Morita, Tomohiro Terada
Format: Article
Language:English
Published: Karger Publishers 2012-11-01
Series:Case Reports in Oncology
Subjects:
Tyrosine kinase inhibitor
Sunitinib
Hemodialysis
Renal cell carcinoma
Pharmacokinetics
Pharmacodynamics
Online Access:http://www.karger.com/Article/FullText/345694

Internet

http://www.karger.com/Article/FullText/345694

Similar Items